rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Steven Altschuler

Director

Company insider

Files Form 4 as: Director, Lexeo Therapeutics; Director, 89bio; Director, WW International; Director, Orchard Therapeutics; Director, Spark Therapeutics; Director, Covista; Director, Mead Johnson Nutrition Co.

In numbers

Trades disclosed
130
Buys
5
Sells
0
Bought
$248K
Sold
$0
Companies
7
Companies where not an officer
7
First trade
10 Mar 2009
Last trade
25 Jun 2026
Last filed
29 Jun 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
LXEO Lexeo TherapeuticsDirector · Biotechnology · last 25 Jun 20260 buys · 0 sells
89bioDirector · last 30 Oct 20250 buys · 0 sells
WW WW InternationalDirector · Consumer Services · last 24 Jun 20250 buys · 0 sells
Orchard TherapeuticsDirector · last 24 Jan 20240 buys · 0 sells
Spark TherapeuticsDirector · last 17 Dec 20191 buy · 0 sells
CVSA CovistaDirector · Education Services · last 6 Nov 20190 buys · 0 sells
Mead Johnson Nutrition CoDirector · last 15 Jun 20174 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
25 Jun 2026filed 29 Jun 2026LXEO Lexeo Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—35,000 at $0.00filing
25 Jun 2026filed 29 Jun 2026LXEO Lexeo Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—35,000 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—40,000 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—7,000 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—12,500 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—25,000 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—27,400 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—45,150 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—56,400 at $0.00filing
26 Jun 2025filed 30 Jun 2025LXEO Lexeo Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—25,000 at $0.00filing
24 Jun 2025filed 26 Jun 2025WW WW Internationaloption or derivative · Consumer ServicesSEC FORM 4 Code M—40,486filing
24 Jun 2025filed 26 Jun 2025WW WW InternationalConsumer ServicesSEC FORM 4 Code M—40,486filing
24 Jun 2025filed 26 Jun 2025WW WW InternationalConsumer ServicesSEC FORM 4 Code D—68,399filing
24 Jun 2025filed 26 Jun 2025WW WW InternationalConsumer ServicesSEC FORM 4 Code A—735filing
3 Feb 2025filed 5 Feb 202589biooption or derivativeSEC FORM 4 Code A—56,400 at $0.00filing
30 Dec 2024filed 2 Jan 2025WW WW Internationaloption or derivative · Consumer ServicesSEC FORM 4 Code A—3,696 at $0.00filing
30 Sep 2024filed 2 Oct 2024WW WW Internationaloption or derivative · Consumer ServicesSEC FORM 4 Code A—3,696 at $0.00filing
1 Jul 2024filed 3 Jul 2024WW WW Internationaloption or derivative · Consumer ServicesSEC FORM 4 Code A—3,696 at $0.00filing
25 Jun 2024filed 27 Jun 2024LXEO Lexeo Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—18,000 at $0.00filing
1 Apr 2024filed 3 Apr 2024WW WW Internationaloption or derivative · Consumer ServicesSEC FORM 4 Code A—3,696 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed5

Buys in green, sells in red, by the company’s sector.

Related people

Jose Manuel OteroChief Operating Officer · Chief Operating Officer at Lexeo Therapeutics, filing Form 4 there in the last year
Richard Nolan TownsendChief Executive Officer · Chief Executive Officer at Lexeo Therapeutics, filing Form 4 there in the last year
Narinder Pal BhallaChief Medical Officer · Chief Medical Officer at Lexeo Therapeutics, filing Form 4 there in the last year
Louis Edward TamayoChief Financial Officer · Chief Financial Officer at Lexeo Therapeutics, filing Form 4 there in the last year
Paula H. CholmondeleyOther role · Director at Lexeo Therapeutics, filing Form 4 there in the last year